BRS3(FM3) - Inflammation Resolution Capacity
(Inflammation Resolution & Lipid Mediator Balance)
1. Mission & Overview
Mission
Enable active termination of inflammation through pro-resolving lipid signals rather than relying on simple immune suppression.
Overview
A functional control point governing active termination of inflammation through pro-resolving lipid mediators (specialised molecules that switch inflammation off) rather than simple suppression of immune activity.
- Modulates cytokine signalling tone across IL-6, TNF-α, and CRP-linked pathways.
- Balances arachidonic-acid inflammatory mediators against EPA/DHA-derived pro-resolving mediators.
- Depends on essential fatty acid balance and antioxidant substrate sufficiency.
2. Primary Biological Effects
↑ resolvins/protectins/maresins; ↑ debris clearance; ↓ unresolved inflammation
3. Phenome Connections
These outcomes describe translational contexts for the FM as an integrated biological capacity. They are not single-mechanism treatment claims. Biology → Phenome Confidence reflects biological relevance to each outcome — not proof that diet or lifestyle alone will improve it. Evidence Confidence (below Key References) reflects how convincing the attached evidence is for the Biology → Phenome relationship on that row. FM confidence uplift: FM confidence may exceed that of any individual child PM only where multiple PMs converge on the same phenome and the integrated FM biology provides additional biological rationale (biological uplift) beyond the individual mechanisms.
These are three independent scores. They are not combined or averaged. A phenome can have Medium registry evidence while individual mechanism rows show different Biology → Phenome and Evidence scores.
1. Phenome Evidence Confidence (Phenome Registry only)
Question: How convincing is the foundational evidence that this phenome is a valid, well-defined functional construct — and that diet-relevant biology can plausibly connect to it?
Not a roll-up of Biology → Phenome Confidence or Evidence Confidence from Primary Mechanism page rows. Those are scored per mechanism; this score is assigned once per phenome at registry level.
Derived from foundational landmark evidence organised in up to three layers: construct validation, biology→phenome linkage, and nutrition→biology modulation. Each layer may include one or many landmark papers depending on registry review.
2. Biology → Phenome Confidence (Primary Mechanism page §3 rows)
Question: If this PM/FM biology were substantially impaired in isolation, how directly would that phenome be expected to suffer — within BRAIN architecture?
How it is derived: Reviewers read the PM/FM definition and biological function first — initially ignoring attached references and whether dietary intervention studies exist. References are reviewed only when scoring Evidence Confidence (below).
Score levels (the value shown on each row as Biology → Phenome Confidence):
- High — primary biological determinant (e.g. noradrenergic signalling → attention; GABA synthesis → calming tone)
- Medium — major contributory determinant, not the sole driver
- Low–Medium — established but indirect, modulatory, or one integrative step removed
- Low — distal, conditional, or weak biological coupling
“Not dietary treatment efficacy” means this score does not ask whether a diet or supplement treats the phenome. It asks whether the biology itself is architecturally relevant. Limited dietary RCT evidence belongs in Evidence Confidence, not here.
3. Evidence Confidence (Primary Mechanism page §3 rows)
Question: How convincing are the attached Key References on that specific row that this biology actually relates to this phenome?
How it is derived: Assigned after Biology → Phenome Confidence, by reviewing only the references on that PM/FM row. Judges whether refs support the relationship — not just mechanism or phenome in isolation.
- High — strong convergent human evidence directly linking mechanism biology to phenome variation
- Medium — multiple human lines supporting the relationship; may include one bridge study with an inferential step
- Low–Medium — convergent translational stack without direct mechanism↔phenome measurement on the row
- Low — mechanistic or preclinical only; mechanism and phenome supported separately but not bridged
Often equal to or lower than Biology → Phenome Confidence. Can occasionally be higher when outcome evidence is stronger than the mechanism's contributory role.
- Biology → Phenome Confidence: Medium
- Synthesis: Resolution-oriented lipid mediator and cytokine-network balance contribute to the inflammatory environment associated with apprehensive worry and perseverative thought. Human intervention evidence (Kiecolt-Glaser et al., 2011) demonstrates that omega-3 supplementation reduced inflammatory cytokine production alongside anxiety symptoms in stressed adults, providing translational support for this Biology → Phenome relationship.
- Key References:
- Slavich & Irwin (2014) — Human Mechanistic
- Marsland et al. (2017) — Human Mechanistic
- Kiecolt-Glaser et al. (2011) — Human Outcome
- Ferguson et al. (2014) — Human Study
- Evidence Confidence: Medium
- Biology → Phenome Confidence: Low
- Synthesis: Inflammation-resolution capacity intersects mitochondrial and reward-processing dysfunction in depression translational models; omega-3 resolution biology provides mechanistic context without direct anhedonia-outcome claims on this FM.
- Key References:
- Evidence Confidence: Low
4. Mechanistic Basis (Integrated FM Narrative)
Inflammation resolution capacity emerges from the coordinated interaction of several primary mechanisms and supporting biological pools.
4.1 Core Primary Mechanisms
-
BRS3-FM3-PM7 — Cytokine Network Modulation Modulates cytokine signalling tone across IL-6, TNF-α, and CRP-linked inflammatory pathways — governing downstream cytokine intensity rather than upstream transcriptional nodes alone.
-
BRS3-FM3-PM8 — Eicosanoid / SPM Balance Balances arachidonic-acid-derived inflammatory mediators against EPA/DHA-derived specialised pro-resolving mediators (SPMs) — governing the shift from pro-inflammatory eicosanoids toward active inflammation resolution.
4.2 Integrated Functional Narrative
Together, cytokine network modulation and eicosanoid/SPM balance operationalise BRS3(FM3) as coordinated inflammation resolution capacity.
At the integrated FM level, this is distinct from simple suppression: resolution requires the right lipid substrate context to terminate inflammatory activity, shift mediator balance, and allow cytokine pressure to fall. Lipid peroxidation control from BRS3-FM2-PM5 remains supportive here by helping preserve the integrity of the lipid environment on which resolution depends [Serhan & Petasis, 2011; Ferguson et al., 2014].
4.3 Suboptimal Function & Its Effects
Inflammation resolution capacity may weaken when habitual EPA/DHA intake and omega-3/omega-6 dietary balance become chronically unfavourable for specialized pro-resolving mediator formation.
Low omega-3 intake may limit EPA/DHA substrate availability for resolvin, protectin, and maresin pathways. Excessive omega-6 dominance, low oily-fish consumption, poor dietary fatty-acid diversity, and chronic inflammatory load may further constrain specialised pro-resolving mediator formation [Serhan & Petasis, 2011].
Oxidative damage to membrane lipids—when BRS3-FM2-PM5 — Lipid Peroxidation Control is strained—may further compromise the lipid environment required for active resolution rather than prolonged cytokine elevation.
These pressures may impair BRS3-FM3-PM7 — Cytokine Network Modulation and weaken BRS3-FM3-PM8 — Eicosanoid / SPM Balance. At the FM level, this may shift BRS3(FM3) toward impaired inflammation resolution capacity.
4.4 Evidence Highlights
Introduction/Summary
The studies below support inflammation resolution capacity as an integrated FM state emerging from coordinated child PM biology — mechanism-qualifying findings that refine framework interpretation, not phenome/outcome science (which belongs in §3).
- Confidence: low-medium
- Evidence Level: mechanistic
- Rationale: In controlled endotoxemia models, high-dose EPA+DHA attenuated fever and downstream cytokines (IL-6, IL-10) while TNF-α remained unchanged — suggesting omega-3s reshape resolution-phase inflammation rather than block initiation [Ferguson et al., 2014].
- Key References:
- Confidence: low-medium
- Evidence Level: mechanistic
- Rationale: Specialized pro-resolving mediators derived from DHA and EPA actively terminate inflammation without suppressing immune surveillance — resolvins, protectins, and maresins inhibit neutrophil infiltration and support macrophage clearance [Serhan & Petasis, 2011].
- Key References:
- Confidence: low-medium
- Evidence Level: mechanistic
- Rationale: High-dose EPA+DHA attenuated fever and downstream cytokines in controlled endotoxemia while TNF-α remained unchanged — consistent with omega-3s reshaping the resolution phase rather than blocking inflammatory initiation [Ferguson et al., 2014].
- Key References:
5. Connected Mechanisms
- BRS1-FM3-PM6 — Neuronal Membrane DHA Incorporation — membrane long-chain PUFA substrate pools feeding specialized pro-resolving mediator formation
- BRS3-FM1-PM1 - NF-kB Signalling Regulation — nF-kB Signalling Regulation
- BRS3-FM1-PM2 - Gut-Derived Inflammatory Signalling — gut-Derived Inflammatory Signalling
- BRS3-FM2-PM5 - Lipid Peroxidation Control — lipid Peroxidation Control
- BRS5-FM1-PM2 — LPS / Endotoxin Containment — gut endotoxin containment upstream of systemic cytokine network tone
- BRS5(FM1) — Gut Barrier Integrity and Immune Interface — gut–immune interface context influencing inflammatory resolution substrate availability
- BRS6(FM1) — Glycaemic–Insulin Stability & Cognitive Energy Availability — post-prandial glycaemic context conditioning inflammatory cytokine expression
6. References
- Serhan and Petasis (2011) — Resolvins and Protectins in Inflammation Resolution
- Ferguson et al. (2014) — Omega‐3 PUFA Supplementation and the Response to Evoked Endotoxemia in Healthy Volunteers
- Kiecolt-Glaser et al. (2011) — A Randomized Controlled Trial
- Song et al. (2023) — A Fatal Blow in Depression
- Gruber et al. (2023) — Impact of Insulin and Insulin Resistance on Brain Dopamine Signalling and Reward
- Slavich & Irwin (2014) — A Social Signal Transduction Theory of Depression
- Marsland et al. (2017) — Systemic Inflammation and Resting State Connectivity of the Default Mode Network